Articles

Further expansions of the pharmaceutical development and manufacturing services of ten23 are happening at the BASE and VIVA facilities to continue to support complex sterile product development, testing, and manufacturing. 

ten23 Expands Sterile Manufacturing Capacity at VIVA 1 Facility 

Novo Nordisk receives the full rights to develop and commercialize the lead program. 

Novo Nordisk Acquires Embark Biotech

Both companies have a focus to developing and commercializing treatments for rare diseases with a strong focus on patients and supporting communities with little to no existing therapeutic options.

Zevra Therapeutics to Acquire Acer Therapeutics 

Cheryl Barton is director of PharmaVision, 

Tumour-infiltrating lymphocyte (TIL) therapies offer a new route to target cancer.

Harnessing the Power of Oncolytic Viruses

Felicity Thomas is Associate Editorial Director of Pharmaceutical Technology, Pharmaceutical Technology Europe, BioPharm International.

European vaccine manufacturing is being boosted with high level investments.  

Booster Shot for Pharma

There are many promising trials in the pipeline that may bring big news for major therapeutic areas.

Clinical Trials and their Impact on the Pharma Industry

Interpreting data and understanding the various components of biologic 
drug substance testing is an important skillset to know as a lab personnel.


Data Integrity's Impact in Drug Substance Testing

Feliza Mirasol is the science editor for 

Bristol Myers Squibb has joined Cellares’ Technology Adoption Partnership program just as Cellares launches operations as an integrated development and manufacturing organization.

Bristol Myers Squibb Joins Cellares Program Focused on Automated Cell Therapy Manufacturing as Cellares is Launched as First IDMO

The Centers for Medicare & Medicaid Services (CMS) has announced the first 10 drugs covered under Medicare Part D selected for negotiation. 

White House Sets Medicare Price Negotiation Targets

Bristol Myers Squibb’s Reblozyl (luspatercept-aamt) is approved as a first-line treatment for anemia in adults with lower-risk myelodysplastic syndromes.

News